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Abstract
Background: Praziquantel at 40 mg/kg in a single dose is the WHO recommended treatment for all forms of
schistosomiasis, but 60 mg/kg is also deployed nationally.
Methodology/Principal Findings: Four trial sites in the Philippines, Mauritania, Tanzania and Brazil enrolled 856 patients
using a common protocol, who were randomised to receive praziquantel 40 mg/kg (n=428) or 60 mg/kg (n=428). While
the sites differed for transmission and infection intensities (highest in Tanzania and lowest in Mauritania), no bias or
heterogeneity across sites was detected for the main efficacy outcomes. The primary efficacy analysis was the comparison of
cure rates on Day 21 in the intent-to-treat population for the pooled data using a logistic model to calculate Odd Ratios
allowing for baseline characteristics and study site. Both doses were highly effective: the Day 21 cure rates were 91.7%
(86.6%–98% at individual sites) with 40 mg/kg and 92.8% (88%–97%) with 60 mg/kg. Secondary parameters were eggs
reduction rates (ERR), change in intensity of infection and reinfection rates at 6 and 12 months. On Day 21 the pooled
estimate of the ERR was 91% in both arms. The Hazard Ratio for reinfections was only significant in Brazil, and in favour of
60 mg/kg on the pooled estimate (40 mg/kg: 34.3%, 60 mg/kg: 23.9%, HR=0.78, 95%CI=[0.63;0.96]). Analysis of safety
could not distinguish between disease- and drug-related events. 666 patients (78%) reported 1327 adverse events (AE) 4 h
post-dosing. The risk of having at least one AE was higher in the 60 than in the 40 mg/kg group (83% vs. 73%, p,0.001). At
24 h post-dosing, 456 patients (54%) had 918 AEs with no difference between arms. The most frequent AE was abdominal
pain at both 4 h and 24 h (40% and 24%).
Conclusion: A higher dose of 60 mg/kg of praziquantel offers no significant efficacy advantage over standard 40 mg/kg for
treating intestinal schistosomiasis caused by either S. mansoni or S. japonicum. The results of this study support WHO
recommendation and should be used to inform policy decisions in the countries.
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Schistosomiasis is a parasitic infection caused by blood flukes
(flatworms) of the class Trematoda: Schistosoma haematobium
(causing urinary schistosomiasis), S. mansoni, S. japonicum, S.
intercalatum and S. mekongi (causing intestinal schistosomiasis). A
recent systematic review of evidence estimates that ,207 million
people (97% in Africa) are affected and ,779 million people are
at risk (85% in Africa) in 76 countries (46 in Africa). With respect
to the mid 1990s, there has been an increase of ,7.3% and
10.9% in infections and population at risk (mostly accounted for
by Africa) but a concomitant (slight) decrease from 29.6% to
26.6% of the ratio between people infected and people at risk,
primarily as the combined result of socio-economic development
and interventions such as sanitation and broader distribution of
praziquantel [1].
Traditionally, schistosomiasis has been attributed a low burden
of disease as quantified by DALY (disability adjusted life years) lost
(1,760,000 estimated in 2002 [2]). However, the real impact of
schistosomiasis infection on people’s health and performance is
more difficult to quantitate. A systematic review and meta-analysis
of disability-related effects of schistosomiasis indicates that the
disability weight of schistosomiasis (2–15%) is much greater than
the previous estimation of 0.5% [3]. Specifically for S. japonicum,a
disability rate of 13% has been calculated (7–46 times greater than
current estimates) [4].
Today praziquantel is the mainstay of schistosomiasis control.
However, while the World Health Organization (WHO) currently
recommends that it should be used in a single dose of 40 mg/kg
for the treatment of both urinary and intestinal schistosomiasis [5],
different doses of praziquantel are being deployed by national
control programmes.
Studies of the dose-response of praziquantel in urinary and
intestinal schistosomiasis are few and incomplete. In particular,
no obvious dose-effect was apparent in a Cochrane systematic
review and meta-analysis of randomised controlled trials of
praziquantel between the doses of 20 to 40 mg/kg for urinary
schistosomiasis [6]. A Cochrane systematic review and meta-
analysis of treatments for intestinal schistosomiasis is under way.
Here, contrary to urinary schistosomiasis, preliminary results
(which were not available when this study was being planned
and conducted) show a dose-response effect between the doses
of 20, 30 and 40 mg/kg with no further gain with doses
.40 mg/kg.
This study was set up to assess whether using praziquantel at
60 mg/kg for intestinal schistosomiasis (caused by either S.
japonicum or S. mansoni) offers advantages over 40 mg/kg. Four
trial sites in the Philippines, Mauritania, Tanzania and Brazil
enrolled patients using a common protocol. The study at each site
was powered to show a difference in cure rates between dosage
groups. The analytical plan was prospectively designed to allow for
reporting the results both for each study site and combined by
individual patients’ data meta-analysis (IPD).
Materials and Methods
Study sites
The studies were conducted in:
N t h ep r o v i n c eo fA g u s a nd e lS u ri nM i n d a n a oI s l a n d ,
Philippines (rural, S. japonicum with year round transmission
during June to September, prevalence 7–11%)
N the Mwanza region, Tanzania (rural, S. mansoni (year-round)
and S. haematobium (February to March), prevalence 34 to 65%)
N the Trarza region, Mauritania (rural, S. mansoni, prevalence
18.7%, S.haematobium prevalence 30.9%, Coinfection 7.3% and
total prevalence 57%)
N Municipality of Sa ˜o Lourenc ¸o da Mata, Pernambuco state,
North-eastern Brazil (urban, S. mansoni (year round), preva-
lence 25%).
The prevalences above are from historical data. The actual
point prevalence found on screening for this study for each site is
reported in the Results section.
Patients
Inclusion criteria. Aged 10–19 years; confirmed Schistosoma
infection with $100 eggs per gram of faeces (epg) using Kato Katz
technique (S. japonicum in the Philippines; S. mansoni in the others,
with mixed infections with S. haematobium allowed in Mauritania);
written informed consent; able and willing to be examined on
follow-up visits and to provide stool samples.
Exclusion criteria. Pregnant or lactating; previous history of
adverse reaction associated with praziquantel; history of acute or
chronic severe disease including hepato-splenic schistosomiasis;
use of praziquantel within the last 30 days or any other medication
that may affect the results of trial (e.g. antibiotics) within the past
week; symptomatic malaria; mixed S. mansoni and S. haematobium
infections in Tanzania.
Parasitological diagnosis
At baseline, Day 21, 6 months and 12 months, stool samples
were taken on two consecutive days and each tested twice. The
mean egg counts are reported.
Study drug
Praziquantel (DistocideH by Shin-Poong, Korea) was procured
by WHO and administered with food after weighing the
participants on a scale by the nearest half tablet according to the
randomization schedule.
Study outcomes
Efficacy. (i) Primary: cure rates (‘‘complete cure’’ defined as
negative stools for Schistosoma eggs) and egg reduction rates (ERR,
‘‘partial cure’’) with the two regimens on Day 21; (ii) Secondary:
reinfection rates at 6 months and 12 months after treatment.
Safety and tolerability: prevalence and intensity of adverse events
(AEs).
The choice of Day 21 as the main efficacy outcome is justified
by the fact that, as praziquantel is not active on immature
schistosomes of less than 24 days, by Day 21 immature S. mansoni
worms will not have yet matured into patent egg-producing
infections. The evaluation of praziquantel efficacy, using duplicate
Kato-Katz slides from two different stool samples, at 3 weeks
showed the highest cure and egg-reduction rates [7].
Recruitment procedures
Screening occurred in the village in Brazil and Mauritania and
at school in the Philippines and Tanzania.
Randomization
Computer generated randomization list with blocks of 4 in a
ratio 1:1 for each regimen.
Allocation concealment
Sealed and numbered envelopes were kept in a locked cabinet
by one responsible person; two different people preparing
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technician blinded as to the treatment.
Sample size calculation
The sample size required at each site was computed at 91
patients per treatment group using 60% and 80% as the cure rates
of praziquantel 40 mg/kg and 60 mg/kg respectively, with 80%
power and 95% confidence. The sample size was adjusted to 109
individuals per treatment group for a total of 218 participants in
consideration of the anticipated 20% of participants who might be
lost to follow-up.
Assessment of risk of bias
The results were expressed as Odds Ratios (OR and 95%
confidence intervals (CI)) for dichotomous outcomes. Adjusted
outcomes (such as cure rates and hazard ratios [HR]) were
analysed by using an inverse variance methodology. Continuous
outcomes were expressed as means and standard deviations.
Study bias was examined through the use of a funnel plot of the
log-transformed OR/HR [log(OR)/Log(HR)] of individual stud-
ies against the precision (1/SE, standard error). Funnel plot
asymmetry was further tested by using the Egger’s method.
For the assessment of heterogeneity, the Cochran’s Q and I
2
test of heterogeneity were performed to detect non-homogeneity
between the estimates of individual studies and by using fixed
effects models. The Mantel-Haenszel method was used to
analyse cure rates. ORs of adjusted cure rates allowing for age,
gender, baseline diarrhoea and nausea were obtained by the
generic inverse variance method. An inverse variance method
was also used to analyse the difference between groups in the
mean of the difference between eggs-per-gram (epg) at Day 21
and Day 0.
The Mantel-Haenszel method was used to analyse the
reinfection rates at day 180 and day 360. The HRs of reinfection
provided by a Cox proportional hazard model were aggregated by
using the generic inverse variance method.
Analyses
While the data were also analysed for each individual study, in
this paper we present specifically the results of the prospectively
defined individual patient data meta-analysis whereby the analysis
was performed by using the same methods as for each study site
(see below) adjusted for the site.
Population. Efficacy and safety analyses were conducted on
the Intent-to-Treat (ITT) population. Missing or incomplete data
were considered as missing.
The same analyses were also conducted on per-protocol
populations (PP1=All patients randomized and evaluable at the
Day 21 visit with no major protocol violations; PP2=All patients
randomized and evaluable at the 12 months visit with no major
protocol deviations) - not reported in this paper as results are
comparable with the ITT analysis.
Study profile and baseline characteristics. Patient
attrition throughout the study was reported according to the
Consort guidelines, accounting for drop-outs and exclusions (in
diagrammatic form).
The baseline characteristics of the patients enrolled are
reported, including basic demography (sex and age) and pre-
treatment values for egg counts and intensities of infection by
treatment group. Continuous variables are presented as mean
+/2 standard deviation.
While allocation to treatment was by computer-generated
random assignment, we checked for possible imbalance between
the groups in terms of baseline conditions and drop-out rates.
Group comparison was carried out using the Student t-test. In the
case of a non-significant Kolmogorov-Smirnov test for normal
data or non-homogeneity of the variances (folded F-test) between
groups, a logarithmic transformation was used. A non-parametric
Wilcoxon sign rank test for matched pairs was performed if the
student t-test applying conditions were still not respected. The
Chi-square test was used to compare frequencies.
Analyses of efficacy
Data presentation. Continuous data are presented as mean
and standard deviation. Dichotomous or multiple categories data
are presented as frequencies and %.
Cure rates are presented as % cured with 95% confidence
intervals (CIs).
Egg count reduction was estimated as: [12(epg2/epg1)6100]
where epg1 and epg2 are the geometric mean of log10
transformed (x+1) numbers of eggs per gram of faeces at pre-
treatment (D0) and Day 21 post-treatment, respectively.
A logarithmic transformation of the egg count values at Day 0
and Day 21 was done. A value of 1 was added to each egg count
value so that the logarithm of zero egg count (for negative result)
could be computed.
Cure rates. A Chi-square test (with correction for continuity)
was used to compare the cure rates at day 21 with 60 mg/kg vs.
40 mg/kg of praziquantel. The relative rates on Day 21 between
the two groups are presented as OR with 95% CIs. A logistic
model was used to evaluate the adjusted OR and 95%CIs on
baseline characteristics such as sex, age, egg counts, intensity of
infection and highly frequent signs, symptoms or positive physical
examination.
For the IPD meta-analysis, the study site was included in the
model. A generalized linear model using a logit link function was
used if heterogeneity was not found; otherwise, a generalized
linear mixed model including random effects was used. In the
latter, treatment effect and the interaction of treatment and study
site were tested as random effects in the model.
Author Summary
Control of urinary and intestinal schistosomiasis is based
on mass administration of praziquantel at the World
Health Organization (WHO) recommended dose of 40 mg/
kg, though some countries use 60 mg/kg. This multi-
country randomized clinical trial compared the efficacy
(cure and egg reduction rates three weeks post-treatment)
and safety of these two doses for treating intestinal
schistosomiasis in 856 patients in Brazil, Mauritania and
Tanzania (Schistosoma mansoni), and The Philippines (S.
japonicum). Transmission and infection intensities varied
across the sites, but there was no bias or heterogeneity in
efficacy outcomes. The two doses are equally effective in
curing intestinal schistosomiasis; the higher dose may be
less well tolerated, though effects are generally mild and
transient. In endemic areas people can be re-infected; one
year post-treatment patients on 60 mg/kg had fewer re-
infections but this finding is difficult to explain. This study
was conducted to respond to the demand for evidence
about the dose of praziquantel when deployed in endemic
countries. The results, along with those of systematic
reviews, support the current WHO recommendation for
using praziquantel at 40 mg/kg and should inform policy
decisions in countries. The Philippines has already changed
from 60 to 40 mg/kg after this study.
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were compared using the analysis of variance for repeat measures
to determine if there was a difference between the two treatment
regimens at baseline (D0) and Day 21. An ANCOVA model of the
D21 and D0 difference with the D0 value as covariate and
treatment group as factor was used as a sensitivity analysis of the
repeated measures ANOVA. The egg reduction rates (ERR) at
Day 21 were calculated and presented descriptively for the two
arms.
For the IPD meta-analysis a general linear model including
study site effect was used. In case of heterogeneity, a model with
random effects was used.
Intensity of infection. The intensity of infection at Day 0
and Day 21 of patients given praziquantel 60 mg/kg or 40 mg/kg
was compared using the ordered logistic regression analysis. The
categories used were: light (1–100 eggs per gram of faeces);
moderate (101–400 epg); heavy (.400 epg).
For the IPD meta-analysis the intensity of infection at Day 0
and Day 21 of patients given praziquantel 60 mg/kg single dose
regimen and praziquantel 40 mg/kg single dose regimen was
compared using a linear model for polytomous dependent variable
using a logit link function and mixed effects if heterogeneity was
found between study sites and adjusted for the study site.
Reinfections. Two approaches were used.
The time to reinfection post-Day 21 was investigated by using
Kaplan-Meier product limit estimates. The median infection-free
survival time was calculated with 95%CIs. Hazard ratios (HR) of
reinfection adjusted by baseline characteristics such as sex, age,
egg counts, intensity of infection and frequently reported signs,
symptoms or positive physical examination was examined with a
Cox proportional hazard model (adjusted for the study site for the
pooled estimate).
We also calculated the rate of infections on Day 180 and on Day
360 at each site and on the pooled data and compared treatment
arms using the Mantel-Haenszel fixed effect OR with 95% CIs.
In addition we calculated the intensity of infection occurring
during follow-up as described above.
Analysis of safety
Safety data were gathered through a questionnaire enquiring on
the occurrence of adverse events (AEs) on Day 0 at 4 hours, Day 1
and Day 21 post-dosing. An AE was defined as any unfavourable
and unintended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with the use of a
medicinal or investigational product, whether or not related to that
product. It is clear that this approach does not allow to distinguish
between disease-related and drug-related events, but only allows
comparing arms for frequency of events, independent of causality.
Recording of the AEs included: (1) date and time of onset, (2)
duration, (3) severity, (4) severity and (5) relationship to treatment.
The report also includes a probable explanation from the
investigator as to the cause of the AE.
The prevalence and intensity of the following signs and
symptoms are assessed: abdominal discomfort, nausea, vomiting,
diarrhoea, anorexia, fever (using an oral thermometer), headache,
dizziness and allergic reaction. The severity of the signs and
symptoms was categorized as ‘‘mild’’, ‘‘moderate’’, ‘‘severe’’ and
‘‘life-threatening’’. The relationship of the signs and symptoms to
treatment was categorized as ‘‘not related’’, ‘‘unlikely’’, ‘‘possible’’,
‘‘probable’’ and ‘‘most probable’’. For the purpose of this study,
Figure 1. Patient attrition. Consort flow diagram of patient attrition * One protocol violation at Day 21 had no data.
doi:10.1371/journal.pntd.0001165.g001
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those followed-up reporting one or more AEs.
The cumulative prevalence of AEs, defined as the presence of at
least one AE in a patient, was determined at 4 hours on Day 0,
Day 1 and Day 21 post-treatment.
AEs, signs and symptoms were classified according to the WHO
Adverse Reaction Terminology dictionary.
Ethics
Patients were explained the scope of the study and signed a
written informed consent (if under 18 years of age, written
informed consent from parents/guardians and individual verbal
assent) before inclusion in the study. The studies were conducted
according to the Helsinki declaration and were approved by the
local (University of the Philippines Manila - College of Medicine
Institutional Review Board, ethics committee of the Institut
National de Recherches en Sante ´ Publique in Mauritania,
National Medical Research Coordinating Committee in Tanza-
nia, Research Ethics Committee of the Aggeu Magalhaes
Research Centre, Oswaldo Cruz Foundation (Fiocruz) in Brazil)
as well as the WHO ethics committees. All sites except Tanzania
were independently monitored.
Results
First Patient First Visit and Last Patient Last Visit were August
2005–August 2006 in the Philippines, August 2005–December
2006 in Mauritania, August 2005–September 2006 in Tanzania
and March 2006–December 2007 in Brazil. A total of 856 patients
were randomised at the four sites to receive praziquantel 40 mg/
kg (n=428) or 60 mg/kg (n=428). The details by site along with
patients’ attrition and baseline characteristics are presented in
Figure 1 and Table 1 respectively.
The point prevalence of intestinal schistosomiasis as derived
from the screening logs was: in Brazil 309/636 (48%); in Tanzania
466/501 (93%); in Mauritania 112/598 (18.7%) for S. mansoni
pure infection (S. haematobium was 185/598 (30.9%) and co-
infections were 44/598 (7.3%) for an overall prevalence of
schistosomiasis of 341/598 (57%); in the Philippines 588/1848
(32%).
The age distribution in each treatment group and gender
category showed that patients aged 10–15 years were over-
represented with respect to a normal distribution in the
Philippines, Mauritania and Tanzania whereas in Brazil the age
distribution was more homogeneous across all ages (10–19 years).
There was no significant difference in age distribution between
treatment groups.
No gender imbalance was apparent except in Tanzania where
males were more prevalent in the 60 mg/kg group (borderline
significance). Fewer males were recruited in Mauritania than in
the other countries (40–45% vs. 50–55%).
Weight was not significantly different between treatment
groups. Patients in Brazil were 3 years older and 15 kg heavier
than in the other countries.
Pre-treatment eggs of schistosoma per gram (epg) of faeces and
intensity of infection were similar between the treatment groups in
the four countries and between the pooled estimates (see below).
Analysis of bias and heterogeneity
While there are only four points to draw the funnel plot, the
cure rates are symmetrical and their distribution is narrow - that is,
a low risk of bias. The funnel plot of the adjusted Day 21 cure rates
is presented as an annex (Figure S1). Similar results were obtained
with the crude rates, the epg, and the hazard ratios of reinfection
(not shown). As for the reinfection rates on follow-up, there was no
bias on Day 180 but bias was found on Day 360.
No substantial heterogeneity (defined as I
2.50%) existed in the
pooled analysis of the 4 study sites for the primary outcome: I
2 for
crude cure rates=8%; adjusted cure rates=47%; epg differences
between Day 21 and Day 0=0%, HR of reinfection=19%,
reinfection rates at Day 180=23%. Instead, the Higgins I
2 for
reinfection rates at Day 360 was 76%. (see reinfection rates
analysis below)
Table 1. Baseline characteristics.
40 mg/kg 60 mg/kg p-value
Age (mean
6 SD)
Philippines 12.5 62.0 12.4 62.0 0.64
Brazil 15.2 62.8 15.0 62.5 0.57
Mauritania 12.6 62.0 12.6 62.1 1.00
Tanzania 12.3 61.8 12.7 62.1 0.07
ALL 13.1 62.4 13.1 62.4 0.71*
Gender
N( % )
Philippines 52.0 (51.0%) 53.0 (52.5%) 0.83
(Males) Brazil 55.0 (56.1%) 53.0 (54.1%) 0.96
Mauritania 40.0 (43.0%) 45.0 (48.4%) 0.46
Tanzania 50.0 (37.0%) 67.0 (49.3%) 0.04
ALL 197.0 (46.0%) 218.0 (50.9%) 0.15*
Weight
(mean
6 SD)
Philippines 32.2 68.8 31.4 69.6 0.53
Brazil 49.0 612.8 48.2 612.1 0.67
Mauritania 32.7 69.4 32.6 69.0 0.89
Tanzania 33.3 66.9 33.3 67.7 1.00
ALL 36.5 611.7 36.1 611.6 0.53*
Epg (mean
6 SD)
Philippines 339.6 6381.0 337.2 6345.6 0.91
Brazil 441.6 6455.8 476.6 6475.1 0.72
Mauritania 278.3 6273.0 378.4 6510.2 0.08
Tanzania 813.5 6713.0 838.8 6789.1 0.83
ALL 488.4 6542.7 531.3 6610.1 0.59*
Intensity of
infection
Philippines moderate 77 (76.2%) 78 (76.5%) 0.97
heavy 24 (23.8%) 24 (23.5%)
Brazil light 0.0 (0.0%) 1.0 (1.0%) 0.83
moderate 65.0 (66.3%) 63.0 (64.3%)
heavy 33.0 (33.7%) 34.0 (34.7%)
Mauritania light 0.0 (0.0%) 0.0 (0.0%) 0.38
moderate 75.0 (80.6%) 70.0 (75.3%)
heavy 18.0 (19.4%) 23.0 (24.7%)
Tanzania light 0.0 (0.0%) 0.0 (0.0%) 0.48
moderate 48.0 (35.6%) 54.0 (39.7%)
heavy 87.0 (64.4%) 82.0 (60.3%)
ALL light 0.0 (0.0%) 1.0 (0.2%) 0.94*
moderate 266.0 (62.1%) 264.0 (61.7%)
heavy 162.0 (37.9%) 163.0 (38.1%)
*General linear mixed models were used to account for the country.
doi:10.1371/journal.pntd.0001165.t001
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Cure rates. The crude (unadjusted) cure rates were 91.7%
(from 86.6% in Tanzania to 98% in Brazil) with 40 mg/kg and
92.8% (from 88% in Tanzania to 97% in the Philippines) with
60 mg/kg (p=0.54 using a general linear mixed model to account
for the study site effect) (Table 2).
No significant difference was seen in the adjusted (for sex, age,
pre-treatment diarrhoea and nausea) ORs of treatment efficacy on
Day 21 (complete cure) between 60 mg/kg and 40 mg/kg both for
the individual studies and for the pooled estimate. In all cases the
95%CI around each estimate crossed the null boundary (Figure 2).
Similarly, no difference was seen with crude (unadjusted) rates in
the ITT as well as the per-protocol populations (not shown).
Egg counts. (Figure 3) At Day 0 (pre-treatment) the mean
eggs per gram (epg) of faeces ranged between 2786273 and
4416456 in the Philippines, Brazil and Mauritania for the 40 mg/
kg arm and between 3376345 and 4766475 for the 60 mg/kg.
The epg was highest in Tanzania with 8136713 and 8386789
respectively. Overall, the mean counts were slightly higher in the
60 mg/kg group in Brazil, Mauritania and Tanzania and similar
in the Philippines.
At Day 21 post-treatment the counts decreased dramatically.
For the 40 mg/kg arm the counts ranged 0 to 3622 in the
Philippines, Brazil and Mauritania but were higher in Tanzania
(336168). In the 60 mg/kg arm, epg in the Philippines and Brazil
decreased to almost 0 (0.161 and 0.160.6, respectively), while in
Mauritania and in Tanzania the counts reached 236161 and
11666 respectively.
Egg reduction rates (ERR). (Table 2) The highest ERR on
Day 21 as compared with Day 0 were 92% for the 40 and the
60 mg/kg treatment group in Brazil and Tanzania. In the other
countries they were at least 89%. The pooled estimate was 91%.
Intensity of Infection. (Figure 4) At Day 0, the intensity of
infection was mostly moderate in all countries (.60% in the
Philippines, Brazil and Mauritania) except Tanzania which had
.60% heavy infections. One case of light infection was recorded
in Brazil. The pooled estimate has 62% for moderate and 38% for
heavy intensity in both the 40 mg/kg and 60 mg/kg groups.
There was no significant difference between the treatment groups.
At Day 21 in the Philippines there were 7 light infections in the
40 and 1 in the 60 mg/kg group; in Brazil 1 light infection on
60 mg/kg; in Mauritania the 40 mg/kg group had 6 light and 1
moderate infection, the 60 mg/kg group had 5 light and 2 heavy
infections; in Tanzania the 40 mg/kg group had 9 light, 4
moderate and 3 heavy infections and the 60 mg/kg group 13, 1
and 1 respectively left. The pooled estimate has 5% for light in
both the 40 mg/kg and 60 mg/kg groups and 1% (40 mg/kg) and
0.2% (60 mg/kg) for moderate intensity. There was no significant
difference between the treatment groups.
6-month and 12-month follow-up reinfection rates
The product-limit estimate of the time to reinfection was
calculated starting from Day 21 restricted to the patients who were
free of parasites throughout Day 360 (12 months).
Table S1 presents mean epg comparisons between groups and
over time. The median infection-free survival and reinfection rates
for each study site are presented as an annex (Table S2). The
Kaplan-Meier curves for the global estimate are presented in
Figure 5.
Reinfection rates were lowest in Mauritania (8% and 3% in the
40 and 60 mg/kg arms respectively) and highest in Tanzania (47%
and 37% respectively). The median infection-free survival was
similar between sites (though this may be an artefact as patients
were seen only twice during follow-up: around Day 180 and Day
360). For the comparison between the two doses, the hazard ratio
(HR) was not significant in all countries except Brazil in favour of
60 mg/kg, and was significant on the pooled estimates (pooled
reinfection rates: 34.3% (95%CI=[29.8; 39.3]) in the 40 mg/kg
arm and 23.9% (95%CI=[20.0; 28.4]) in the 60 mg/kg arm;
HR=0.78, 95%CI=[0.63;0.96])
In addition to the Kaplan-Meier estimates presented above, we
also compared the reinfection rates occurring at 6 and 12 months
of follow-up for each individual country as well as for the pooled
data (Figure 6). The pooled OR(95%CIs) were 1.70 (1.18, 2.46,
p=0.0047) at 6 months and 1.41 (1.02, 1.95, p=0.0037) at 12
months, both showing a difference in favour of the 60 mg/kg
group. The 76% I
2 on Day 360 is explained by the OR in
Table 2. Crude (unadjusted) Day 21 cure rates and reduction rates between Day 0 and Day 21.
40 mg/kg 60 mg/kg
% 95%CI % 95%CI p-value
Philippines 92.16% (85.28%; 95.97%) 97.03% (91.63%; 98.98%) 0.13
Brazil 97.96% (92.86%; 99.44%) 94.90% (88.61%; 97.80%) 0.25
Mauritania 91.40% (83.93%; 95.58%) 92.47% (85.27%; 96.31%) 0.79
Tanzania 86.55% (79.27%; 91.55%) 88.00% (81.14%; 92.59%) 0.73
ALL 91.75% (88.69%; 94.03%) 92.81% (89.92%; 94.91%) 0.54*
Day 21 Egg Day 21 Egg
N GeoMean Reduction N GeoMean Reduction
Philippines 101 1.09 90.1% 99 1.01 90.8%
Brazil 96 1.00 91.7% 94 1.01 91.8%
Mauritania 92 1.10 89.2% 93 1.13 89.6%
Tanzania 119 1.27 91.9% 125 1.20 92.3%
ALL 408 1.12 90.9% 411 1.09 91.3%
*General linear mixed models were used to account for the country.
ERR: eggs reduction rate.
doi:10.1371/journal.pntd.0001165.t002
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the 388 total recrudescences occurred at 6 months. The difference
was significant on both occasions in Brazil, and borderline in
Tanzania at 6 months and the Philippines at 12 months.
Intensity of infection on day 180 raised again in all countries as
intensity was at least light in .20–25% of the patients in the
Philippines, Brazil and Tanzania. In Mauritania intensity was
moderate or heavy in 3% of the patients. The pooled estimate had
22.8% for light, 3.4% moderate and 1.3% for heavy intensity in
the 40 mg/kg group and 12.6% for light, 3.2% moderate and
1.6% for heavy intensity in the 60 mg/kg groups (Table S3).
At Day 360 in the Philippines the intensity of infection was more
pronounced. While, compared to Day 180, the proportion of light
intensity infections remained stable in all countries except in
Tanzania (where it increased dramatically), there were more
moderate intensity infection (9% vs 13% in the Philippines, 3% vs
6% in Brazil, 2% vs 3% in Mauritania and 8% vs 14% in
Tanzania). The pooled estimate has 30% vs 23% for light intensity
in the 40 mg/kg vs. 60 mg/kg groups, 8% vs. 7% for moderate
intensity and 3% vs. 3% for heavy intensity.
There was no significant difference between the treatment
groups in the intensity classes on either Day 180 or Day 360.
Safety analysis
Frequency of AEs. The number of patients with AEs and the
number of AEs decreased over time (Figure 7). These results reflect
Figure 2. Day 21 crude and adjusted cure rates. Forest plot of the Day 21 crude and adjusted cure rates.
doi:10.1371/journal.pntd.0001165.g002
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Day 21c.
doi:10.1371/journal.pntd.0001165.g003
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doi:10.1371/journal.pntd.0001165.g004
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of the disease itself.
Overall 666 patients (78%) reported a total of 1327 AEs 4 hours
post-dosing (Table S4). The risk of having at least one AE was
higher in the 60 than in the 40 mg/kg group (83% vs. 73%, OR
0.54, 95%CI 0.39–0.76, Chi-square p-value,0.001). The propor-
tion of patients with AEs varied across sites from 66% in the
Philippines to 92% in Tanzania. (Table 3)
At 21 hours post-dosing, 456 patients (54%) reported 918 AEs.
There was no difference between the two doses (OR 0.92, 95%CI
0.68–1.17), p=0.4).
At Day 21, 114 patients (13%) had 189 AEs with no difference
between the groups.
Type and severity of AEs. The most frequent AEs (those
occurring with .2% frequency at any visit between 4 hours,
24 hours and 21 days) are summarized in Table 3 by dose and
severity. The most frequent AE was abdominal pain at both 4 and
24 hours (40% and 24% respectively of all AEs at either visit).
Other AEs that contributed .10% on both visits were diarrhoea
and headache.
At 4 hours, regarding the most prevalent AEs, respectively in
the 40 and 60 mg/kg group, severe intensity was reported for
abdominal pain (1% (n=2) and 1% (n=2)), allergy (8% (n=1)
and 7% (n=1)), diarrhoea (1% (n=1) and 4% (n=5)), dizziness
(2% (n=1) and 0%), and vomiting (2% (n=1) and 1% (n=1)).
Moderate intensity were also reported for abdominal pain (34%
(n=90) and 46% (n=125)), allergy (17% (n=2) and 29% (n=4)),
diarrhoea (26% (n=30) and 25% (n=30)), dizziness (10% (n=5)
and 9% (n=5)), headache (19% (n=14) and 20% (n=14)), nausea
(20% (n=12) and 20% (n=14)) and vomiting (20% (n=8) and
22% (n=18)).
At 24 hours, respectively in the 40 and 60 mg/kg, severe
intensity was reported for allergy (5% (n=2) and 10% (n=4)),
anorexia (6% (n=1) and 0%), chest tightness (0% and 17% (n=1/
6)) and diarrhoea (4% (n=2) and 8% (n=5)). Moderate intensities
were observed for abdominal pain (26% (n=30) and 29% (n=32)),
allergy (21% (n=8) and 37% (n=15)), anorexia (44% (n=7) and
50% (n=7)) diarrhoea (40% (n=21) and 41%(n=27)), dizziness
(3% (n=1) and 7% (n=3)), fever (7% (n=1) and 6% (n=1))
headache (20% (n=20) and 18% (n=18)), nausea (12% (n=4) and
19% (n=6)), and vomiting (14% (n=2) and 33% (n=8)).
At Day 21, there was no severe AE.
Only one event (abdominal pain in Mauritania at 4 hours) was
reported as serious.
Drug-event relationship for AEs. At 4 hours post-dosing,
of the most common AEs occurring in the 40 mg/kg group, the
event was judged to be as ‘‘most probably’’ or ‘‘probably’’ related
to the drug in 19% and 25% of cases for abdominal pain, 16% and
29% for diarrhoea, 10% and 24% for dizziness, 2% and 23% for
headache, and 8% and 19% for vomiting. Most probable and
probable relationships to treatment in the 60 mg/kg group were
also reported for abdominal pain (21% and 25%), diarrhoea (12%
and 34%), dizziness (5% and 31%), headache (1% and 21%),
nausea (27% and 22%) and vomiting (18% and 36%).
Figure 5. Infection-free survival curves. Kaplan-Meier infection-free survival curves for all sites combined.
doi:10.1371/journal.pntd.0001165.g005
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probably’’ and ‘‘probably’’ related to the drug were for abdominal
pain 26% and 55%, diarrhoea 12% and 72%, dizziness 2% and
34%, headache 2% and 39% and vomiting 7% and 64%. Most
probable and probable relationships to treatment in the 60 mg/kg
group were also reported for abdominal pain (25% and 58%),
diarrhoea (20% and 79%), dizziness (2% and 34%), headache (2%
and 41%), nausea (19% and 55%) and vomiting (4% and 46%).
On Day 21 one case of dizziness in Brazil and three of chest
tightness in Tanzania were judged to be probably related to
treatment.
Discussion
This study shows that a higher dose of 60 mg/kg of
praziquantel offers no significant efficacy advantage over standard
40 mg/kg for treating intestinal schistosomiasis caused by either S.
mansoni or S. japonicum when assessed three weeks (21 Days) post-
dosing. With 40 mg/kg of praziquantel cure rates are .91% at all
sites except Tanzania (87–88%) and egg reduction rates are .89%
by Day 21. During long-term follow-up at 6 and 12 months,
reinfection rates were higher in the group receiving 40 mg/kg.
Patients treated with 60 mg/kg had a higher risk of adverse events
occurring immediately post-dosing (4 hours), while no difference
was seen 24 hours or 21 days later. The results presented are
based on the intent-to-treat population and are confirmed by other
analyses on per-protocol population as well as various sensitivity
analyses. While the sites differed in terms of transmission and
infection intensities, there was no bias or heterogeneity across sites
for the main efficacy outcomes except reinfection rates at one year
of follow-up.
Together, these results support the current WHO recommen-
dation of deploying praziquantel at 40 mg/kg.
These studies were conducted to respond to the demand for
evidence about the correct dose of praziquantel when used by
Figure 6. Reinfection rates at 180 and 360 days of follow-up. Forest plot of reinfection rates with 40 and 60 mg/kg at 180 and 360 days of
follow-up.
doi:10.1371/journal.pntd.0001165.g006
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multicentre study with a master protocol whereby each site will
follow the same protocol and be powered to show a difference
between expected cure rates, and to have results combined
prospectively for an individual patient meta-analysis.
Prevalence of screening of intestinal schistosomiasis infection
ranged 25% (Brazil)–57% (Mauritania) and the rate of reinfection
one year post-treatment ranged from 9% (Mauritania) to 44%
(Tanzania) between the two treatment arms. Of all sites Tanzania
had the most intense infections, the lowest cure rates (though with
high egg reduction rates), and the highest reinfection rates - all
testifying high transmission intensity.
Reinfections were more frequent in the 40 than in the 60 mg/
kg group at each site, but the difference was significant only for
Brazil and the pooled Kaplan-Meier analysis. The difference
between the two arms was already significant on aggregate and for
Brazil by Day 180, when 40% of reinfections had occurred.
However, there was no difference between the two groups in terms
of intensity classes. It is difficult to explain how a single dose of
praziquantel could affect the risk of reinfection in the following 12
months. Indeed the difference could be a random effect. However,
the Kato-Katz method has been reported to overestimate cure
rates [8] (although here two duplicates were done on consecutive
days were used) and it is hence possible that it failed to identify low
egg counts on Day 21; the cases identified would then result from a
mixture of undetected failures and true reinfections.
Praziquantel treatment of either urinary or intestinal schistoso-
miasis is known to modify both humoral and cellular responses
(like age does). (see for instance Mutapi et al, 2003 [9]). It remains
to be investigated whether the higher dose could elicit a greater
post-treatment antibody and cytokine shift.
The dose-plasma concentration relationship of praziquantel is
poorly know. A study conducted in healthy adult volunteers with
5, 10, 20, 50 mg/kg showed with increasing doses (i) higher
exposure (exponential increase of Cmax, AUC0–24); (ii) more rapid
absorption (significant reduction of Tmax); (iii) slightly reduced tK
[10]. However, no study in the target population (infected school-
age children) has produced pharmacokinetic and pharmacokinet-
ic/pharmacodynamic information on dose-concentration and
dose-effects.
Based on data from the above-mentioned study in volunteers
the doses of 40 and 60 mg/kg (neither have data in the above
study) would be expected to produce AUC0–24 (ng*h/mL) of 2900
and 4600 or 2100 and 8600, respectively depending on whether a
linear or exponential relationship applies - meaning that the AUC
obtained with a dose of 60 mg/kg (1.5 times higher) would be 1.6
or 4 times higher than with 40 mg/kg respectively. For the
40 mg/kg dose, this is coherent with other studies: for comparison,
a dose of 40 mg/kg produced AUC0–24 ranging 2,110-
4.098 ng*h/mL when given in fasting conditions to adult healthy
volunteers, but was ,4 times higher (15,928 ng*h/mL) in patients
[11]. However, without drug levels this remains in the realm of
speculation. In addition, bioavailability (and thus exposure) is
known to have high inter-individual variability, and to change
between an empty stomach and with food (and the type of food:
higher with carbohydrates than fat [12]) as well as the brand of the
product and between health and disease. Finally, there are no data
at present to correlate exposure and effects for praziquantel. It is
unfortunate that this study could not collect blood samples for
drug level determination. In any case, the higher exposure
expected with 60 mg/kg did not translate in a sizeable efficacy
advantage in this study but may entail a higher risk of toxicity (at
Figure 7. Adverse events at 4 hours, 24 hours and 21 days. Number of adverse events (AEs) by treatment group at 4 hours, 24 hours and 21
days post-dosing.
doi:10.1371/journal.pntd.0001165.g007
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generally mild and transient.
A limitation of this trial is that it was designed with a superiority
hypothesis expecting the 60 and 40 mg/kg doses to be 80% and
60% effective at each site. This assumption (which was based on
the recommendations made at the 1991 WHO expert committee
[5]) was disproved by the finding that the cure rates ranged 88–
97% (92.8% on aggregate) with 60 mg/kg and 87–98% (91.7% on
aggregate) with 40 mg/kg. A non-inferiority trial design would
have been more appropriate. The question is whether with such
design the current trial would support the non-inferiority of
40 mg/kg with respect to 60 mg/kg. Assuming the cure rate of the
reference treatment (60 mg/kg) to be 93% and accepting a
difference (d) of 6%, with a precision (a)=0.015 and a power (1-
ß)=90% a study enrolling 428 patients per arm with cure rates of
91.7% and 92.8% (difference=1.1, 95%CI 23.63, +5.75) would
be within the 6% d margins and thus support the non-inferiority of
the 40 vs. 60 mg/kg dose.
Another issue is with the safety evaluation. Here, any event
occurring after drug intake (starting 4 hours after administration)
was conservatively reported as an adverse event (AE), and their
incidence, type and severity compared between treatment groups.
However, the presence and grading before drug administration
was not recorded - it is thus not possible to describe the treatment-
emergent signs and symptoms (i.e. those that were not present pre-
treatment or worsened with the treatment), and to differentiate
between the events related to the disease and those that may be
caused by the drug. Tanzania reported more events than the other
sites - which may be related also to the fact that the Tanzanian
patients were more heavily infected than the others.
The results of this study, along with those of systematic reviews,
should be used to inform policy decisions in the countries [5].
Single dose treatment ensures high population compliance with
treatment which would not be possible with spaced doses of
40 mk/kg praziquantel [6]. The Philippines has already changed
from 60 to 40 mg/kg after considering the local results [13].
Reliable, up-to-date evidence is needed for policy decisions. As
mentioned above, a yet unpublished Cochrane systematic review
of treatments of schistosomiasis mansoni found a dose-effect in
the cure rates of praziquantel up to 40 mg/kg and no gain
beyond this dose. In contrast, no dose-effect was detected in
schistosomiasis haematobia [6]. Of note, only 3 of the 10
praziquantel studies of the urinary and 8 the 20 of the mansoni
review had been conducted in the past 30 years - all the others
were older. One single treatment policy is practical but may not
fit all cases. For areas where both intestinal and urinary
schistosomiasis coexist the dose of 40 mg/kg is expected to cure
both. In an area of Egypt where schistosome parasites were
thought to be less responsive to a 40 mg/kg dose of praziquantel,
no increase in drug failures was noted following 10 years of drug
pressure at this dosage [14]. With the lower dose vigilance is
required to ensure that treatment failures and possible resistance
can be detected early, particularly for special cases (such as areas
where praziquantel efficacy is reportedly suboptimal). There is
also a need for information on exposure post-dosing (drug levels)
in target populations (esp. school-age children) and how it
correlates with efficacy and safety.
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